Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
BCLS II Investco, LP - 12 May 2026 SCHEDULE 13D/A Report for NewAmsterdam Pharma Company N.V. Ordinary Shares, nominal value Euro 0.12 per share (NAMS)
- Filing manager
- BCLS II Investco, LP
- Reporting owner
- BCLS Fund III Investments, LP
- Beneficially owned shares
- 2,059,896 shares
- Large-stake signal
-
Ownership
1.8%Beneficial ownership of this reported class.
Shares
2,059,896 sharesShares beneficially owned as disclosed.
Event date
12 May 2026Date tied to the ownership event or amendment.
Accepted by SEC
14 May 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 1.8%
- Symbol
- NAMS
- Shares outstanding
- 117,039,545 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 14 May 2026, 19:52:23 UTC
- Event date
- 12 May 2026
- Prior SEC filing
- 04 Dec 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
BCLS II Investco, LP disclosed 1.8% ownership in NewAmsterdam Pharma Company N.V. Ordinary Shares, nominal value Euro 0.12 per share (NAMS) on 12 May 2026.
Key facts
- BCLS II Investco, LP filed SCHEDULE 13D/A for NewAmsterdam Pharma Company N.V. Ordinary Shares, nominal value Euro 0.12 per share (NAMS).
- Disclosed ownership: 1.8%.
- Date of event: 12 May 2026.
Change
- Previous schedule filing date: 04 Dec 2025.
- Current filing was accepted on 14 May 2026, 19:52.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (6)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BCLS Fund III Investments, LP | 1.8% | 2,059,896 | 0 | 2,059,896 | /s/ Adam Koppel | Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC | 0001952107 |
| Bain Capital Life Sciences Opportunities III, LP | 1.1% | 1,257,141 | 0 | 1,257,141 | /s/ Adam Koppel | Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC | 0001950105 |
| Bain Capital Life Sciences Fund II, L.P. | 0.08% | 89,142 | 0 | 89,142 | /s/ Adam Koppel | Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC | 0001773187 |
| BCLS II Investco, LP | 0.1% | 114,017 | 0 | 114,017 | /s/ Adam Koppel | Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC | 0001818893 |
| BCLS II Equity Opportunities, LP | 0.32% | 375,512 | 0 | 375,512 | /s/ Adam Koppel | Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC | 0001814474 |
| BCIP Life Sciences Associates, LP | 0.01% | 10,857 | 0 | 10,857 | /s/ Adam Koppel | Adam Koppel, Authorized Signatory of Boylston Coinvestors, LLC | 0001702921 |
CIK / CUSIP context first